Sign In

News Story

News & Views

ACS releases lobular breast cancer special report

​On Oct. 7, ACS released Lobular Breast Cancer Statistics, 2025, a report on occurrence and outcomes in the United States for this subtype of breast cancer. Findings show an estimated 33,600 women will be diagnosed with lobular breast cancer or invasive lobular carcinoma (ILC) this year. Ranked separately, the disease would be the seventh most common cancer among women in the US. The report also finds that incidence rates for ILC have increased more steeply (2.8% per year) than all other breast cancers combined (0.8% per year) from 2012 to 2021. The report is to be published in the journal Cancer, an international, interdisciplinary journal of the American Cancer Society. 

Other key findings from the report include: 

  • Similar to other breast cancers, the steepest rise in ILC incidence is among Asian American/Pacific Islander women, with an increase of 4.4% per year from 2012 to 2021. 

  • White women have the highest incidence rate of ILC (14.7 per 100,000 women), with Black women ranking second (11 per 100,000). 

  • Survival for women diagnosed with ILC is slightly higher than that for ductal breast cancer in the first seven years after diagnosis and for localized-stage disease, but lower for both regional (78.2% versus 76.4%) and distant-stage disease (19.6% versus 12.1%) at 10 years after diagnosis. 

Angela Giaquinto, MSPH, associate scientist, Cancer Surveillance Research, was the lead author of the report. Rebecca Siegel, MPH, senior scientific director, Cancer Surveillance Research, was senior author of the study. Dr. Ahmedin Jemal, senior vice president, Surveillance, Prevention, & Health Services Research (SPHeRe), also contributed to this report. 
back to top